Month: September 2026

To Nasdaq Copenhagen A/S

Executive Management Bernstorffsgade 40 DK-1577 Copenhagen V www.rd.dk Telephone +45 7012 5300 14 September 2026

Opening of new fixed-rate bonds

Realkredit Danmark will open new callable fixed-rate mortgage covered bonds (SDRO) with the following characteristics:

Coupon	Series	Amortisation	Closing date	Maturity
5,0 %	23S	Annuity	31-08-2029	01-10-2059
5,0 %	27S	Annuity*	31-08-2029	01-10-2059
4,0 %	22S	Annuity	31-08-2029	01-10-2049

*) with option on up to 10 years interest only.

The mortgage covered bond will be issued in DKK from Capital Centre S. The mortgage covered bond will be used to fund loans with maturities up to 20 and 30 years, respectively.

The Executive Management

Any additional questions should be addressed to Senior dealer, Thomas Manthorpe, phone +45 45 13 20 20.

Attachment

• 20260914 Åbning af 23S, 27S og 22S – sep 2026_uk

Executive appointments strengthen Pasqal’s product strategy and global people organization as the company advances the commercial deployment of neutral-atom quantum computing

PARIS and NEW YORK, Sept. 14, 2026 (GLOBE NEWSWIRE) — Pasqal (NASDAQ: PSQL), a global leader in neutral-atom quantum computing, today announced the appointment of Roberto Mauro as Chief Product Officer (CPO) and Joëlle Lumb as Chief Human Resources Officer (CHRO). The appointments strengthen Pasqal’s executive leadership team as the company sharpens its product strategy, expands its global operations and builds the organizational capabilities required to support its next phase of growth.

As Chief Product Officer, Roberto will lead Pasqal’s end-to-end product strategy and roadmap, focusing development on priority customer needs and integrated offerings across hardware, software, cloud and services. He will also align teams around key product priorities to accelerate customer adoption and support the development of a scalable, high-margin business.

As Chief Human Resources Officer, Joëlle will lead Pasqal’s global people strategy, organizational transformation, leadership development and culture. She will work across the company to develop the talent, operating structures and capabilities required to support continued growth and international expansion.

“Pasqal’s ability to translate scientific leadership into meaningful customer outcomes will depend on the strength of both our products and our organization,” said Wasiq Bokhari, Chief Executive Officer of Pasqal. “Roberto combines deep technology and product expertise with a strong understanding of our customers and markets. Joëlle brings extensive experience helping global organizations navigate growth and transformation. Their leadership will be instrumental as we focus our product portfolio, strengthen execution and prepare Pasqal to operate at greater scale.”

Roberto Mauro Appointed Chief Product Officer

Roberto brings 30 years of international experience spanning strategy, product management, business development and innovation across Europe, Asia and the United States. Since joining Pasqal in January 2024, he has helped build the company’s Asia-Pacific presence with an initial focus on Korea, secured public and private funding, developed strategic research collaborations and advanced opportunities in Japan, Taiwan and Singapore. Previously, he spent two decades in senior leadership roles at Samsung, where he led technology investments and partnerships focused on data, artificial intelligence and quantum technologies, and held international business development roles at Cisco. Roberto has worked in quantum technology since 2019.

“Pasqal’s research and development organization is world-class, and our opportunity is to complement that strength with a product organization built around customers and the outcomes that matter most to them,” said Roberto. “I look forward to working across Pasqal to translate our technology into integrated, scalable offerings that accelerate customer adoption worldwide.”

Roberto holds a Master of Science in Engineering from Politecnico di Milano and an MBA from IMD.

Joëlle Lumb Appointed Chief Human Resources Officer

Joëlle brings more than 15 years of C-suite experience leading people strategies and organizational transformation across complex international businesses. Her expertise includes organizational design, culture and leadership development, talent strategy, post-merger integration, spin-offs, IPO readiness and restructuring. Before joining Pasqal, she held senior human resources leadership roles at NielsenIQ and Nielsen, overseeing regional and global people strategies across Europe, the Middle East, Africa and other international markets.

“Pasqal is bringing together exceptional scientific, engineering and commercial talent to build a transformative technology company,” said Joëlle. “My priority will be to help create the leadership capabilities, organizational clarity and inclusive culture that enable our people to do their best work and support Pasqal’s successful growth across markets.”

Joëlle holds an executive master’s degree in human resources from ESSEC Business School and an engineering degree in agronomy from ENSAR.

Contacts

Investors
investors@pasqal.com

Media
pr@pasqal.com

About Pasqal
Pasqal (Nasdaq: PSQL) helps organizations tackle problems that are difficult or impossible to solve with conventional computing methods alone. Founded in 2019 on Nobel Prize–winning research, Pasqal builds and operates neutral-atom quantum computers, delivered with a full software stack, for industry, science, and governments. Pasqal’s production-ready systems are available both on-premises and through the cloud, enabling organizations to harness quantum computing without requiring in-house quantum expertise. A single hardware platform supports analog workloads today and is designed to evolve toward fault-tolerant quantum computing in the future.

Headquartered in France with operations globally, Pasqal’s quantum computing systems are used by customers across energy, financial services and advanced materials to address complex challenges. Pasqal’s customers include Saudi Aramco, Crédit Agricole CIB, LG Electronics and supported by partnerships with NVIDIA and IBM (Pasqal is part of the IBM Quantum Network).

Forward-Looking Statements
Certain statements herein may be considered “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “might”, “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “could,” “plan,” “predict,” “project”, “forecast,” “potential,” “seem,” “seek,” “target,” “possible,” “future,” “outlook” or similar terminology or expressions that predict or indicate future events or trends. These forward-looking statements include, but are not limited to, statements regarding future events, including Pasqal’s ability to accelerate global deployment of its quantum computing platform.

These statements are based on current expectations and are not predictions of actual performance. They are provided for illustrative purposes only and must not be relied on as a guarantee, prediction or definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and are beyond the control of Pasqal. These statements are subject to known and unknown risks and uncertainties and assumptions regarding Pasqal’s business, and actual results may differ materially. These risks and uncertainties include, but are not limited to: general economic, political, social and business conditions; uncertainty or changes with respect to laws and regulations; risks related to Pasqal’s indebtedness; the risk from Pasqal pursuing an emerging technology, facing significant technical challenges and the potential that it may not achieve commercialization or market acceptance; Pasqal’s reliance on strategic partners and other third parties; Pasqal’s ability to maintain, protect and defend its intellectual property rights; and other risks that will be detailed from time to time in filings with the U.S. Securities and Exchange Commission (the “SEC”). The foregoing list of risk factors is not exhaustive. There may be additional risks that Pasqal does not know or currently believes are immaterial that could also cause actual results to differ from those contained in forward-looking statements. In addition, forward-looking statements provide Pasqal’s expectations, plans and forecasts of future events and views as of the date of this communication. While Pasqal may elect to update these forward-looking statements in the future, Pasqal specifically disclaims any obligation to do so.

ANNOUNCEMENT

A.P. Møller – Mærsk A/S – Transactions in connection with share buy-back program

On 5 February 2026, A.P. Møller – Mærsk A/S (the “Company”) announced a share buy-back program of up to DKK 6.3bn (around USD 1bn) to be executed over a period of 12 months. The second phase of the share buy-back program will run from 13 August 2026 up to 29 January 2027. The shares to be acquired will be limited to a total market value of DKK 3.15 billion (around USD 500m).

The share buy-back program will be executed under EU Commission Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 (the “Safe Harbour Regulation”)

The following transactions have been made under the program in the period 7 September to 11 September 2026:                        

	Number of A shares	Average purchase price A shares, DKK	Transaction value, A shares, DKK
Accumulated, last announcement	42,948		699,222,680
7 September 2026	250	21,472.8000	5,368,200
8 September 2026	250	21,454.0800	5,363,520
9 September 2026	250	21,330.4000	5,332,600
10 September 2026	250	21,967.6000	5,491,900
11 September 2026	250	21,595.1200	5,398,780
Total 7-11 September 2026	1,250		26,955,000
Accumulated in the second phase of the program	5,950		123,823,310
Accumulated under the program	44,198		726,177,680
	Number of B shares	Average purchase price B shares, DKK	Transaction value, B shares, DKK
Accumulated, last announcement (market and the Foundation)	171,792		2,860,222,955
7 September 2026	877	22,354.9715	19,605,310
8 September 2026	877	22,343.8655	19,595,570
9 September 2026	877	22,150.8552	19,426,300
10 September 2026	877	22,853.1927	20,042,250
11 September 2026	877	22,401.7104	19,646,300
Total 7-11 September 2026	4,385		98,315,730
Bought from the Foundation*	615	22,420.9191	13,788,865
Accumulated in the second phase of the program (market and the Foundation)	23,800		514,459,275
Accumulated under the program (market and the Foundation)	176,792		2,972,327,550

*) According to a separate agreement, A.P. Møller og Hustru Chastine Mc-Kinney Møllers Familiefond (the Foundation) participates on a pro rata basis to the shares purchased in the share buy-back program.

With the transactions stated above, the Company owns a total of 44,198 A shares and 236,831 B shares as treasury shares, corresponding to 1.91% of the share capital.

Details of each transaction are included as appendix.

Copenhagen, 14 September 2026

Contact persons:
Head of Investor Relations, Martin Dunwoodie, tel. +45 3363 3484
Head of Media Relations, Jesper Lov, tel. +45 6114 1521

Page 1 of 1

Attachments

• Announcement – Transactions in connection with share buy-back program – week 37 2026
• Daily transactions in connection with share buy-back program – week 37 2026

PARSIPPANY, N.J. and TEL AVIV, Israel, Sept. 14, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), a global biopharmaceutical company, today announced that its ordinary shares will begin trading today directly on the New York Stock Exchange (NYSE) completing the company’s planned transition from its American Depositary Shares (ADSs) program. Teva’s shares continue to trade under the same ticker symbol “TEVA” on both the NYSE and the Tel Aviv Stock Exchange (TASE).

“Today marks another meaningful milestone in Teva’s transformation,” said Richard Francis, President and CEO of Teva. “The trading of our ordinary shares on the NYSE is expected to broaden investor access to our shares and reflects the momentum we are building through our Pivot to Growth strategy. We remain focused on delivering for patients, driving sustainable growth, and accelerating our transformation into a leading innovative biopharmaceutical company.”

“Our move to a direct ordinary share listing is an important step in strengthening our position in the U.S. capital markets,” said Eli Kalif, Executive Vice President, and Chief Financial Officer of Teva. “Together with our recent return to investment-grade credit ratings from all three major ratings agencies, this milestone demonstrates the strength of our financial transformation, expands our access to investors and enhances our ability to invest for long-term growth.”

Teva’s direct listing comes as the company continues to deliver against its Pivot to Growth strategy, transforming into a leading biopharmaceutical company, driven by a fast-growing innovative medicines portfolio and powered by a leading generics business. Year to date its three flagship innovative brands, AUSTEDO^®, AJOVY^®, and UZEDY^®, have grown collectively by more than 40% year-over-year*,  with expected 2026 revenues of  approximately $3.7 billion. Investment-grade ratings across all three major agencies further underscore Teva’s financial strength, disciplined execution, and continued debt reduction. With multiple near-term pipeline and commercial catalysts ahead, including an innovative pipeline with a potential of more than $10 billion in peak revenues, Teva is well positioned to expand margins, grow earnings and create significant long-term shareholder value.

About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars, and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All in for Better Health. To learn more about how, visit www.tevapharm.com.

Cautionary Note Regarding Forward Looking Statements
This Press Release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. These forward-looking statements include statements concerning our plans, strategies, objectives, and any other information that is not historical information. You can identify these forward-looking statements by the use of words such as “will,” “should,” “expect,” “anticipate,” “may,” “project,” “intend,” “plan,” “believe,” “transition” and other words and terms of similar meaning and expression in connection with any discussion of future performance developments. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully implement the process for terminating our ADS program and directly list our ordinary shares in lieu of the ADSs on the NYSE and to achieve our aims as a result of such process, as described in Part II, Item 5 of our Quarterly Report on Form 10-Q for the second quarter of 2026; our ability to successfully execute on our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and to profitably commercialize our innovative medicines and biosimilar portfolio, whether organically or through business development, to sustain and focus our portfolio of generic medicines, and to execute on our organizational transformation and to achieve expected cost savings; our significant indebtedness, which may limit our ability to attract investors, incur additional indebtedness, engage in additional transactions or make new investments; and other factors discussed in our Quarterly Report on Form 10-Q for the second quarter of 2026 and in our Annual Report on Form 10-K for the year ended December 31, 2025, including in the sections captioned “Risk Factors” and “Other Information.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.

Teva Media Inquiries:
TevaCommunicationsNorthAmerica@tevapharm.com
Teva Investor Relations Inquiries:
TevaIR@Tevapharm.com

*As reported in our Q2 2026 financial results

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/12f4d600-2bc1-4523-a309-25fd649b40b1

Continuum-1, a Satellogic-built Earth Observation Satellite Acquired by HEO, has Completed Two Extended Proximity Operations Periods

PARIS, Sept. 14, 2026 (GLOBE NEWSWIRE) — Satellogic Inc. (NASDAQ: SATL), the infrastructure company for Persistent Global Intelligence (PGI), today confirmed that its flight software ran the maneuvers behind the second phase of HEO’s Rendezvous and Proximity Operations (RPO) campaign, in which an Earth observation satellite held position around a derelict CZ-2C rocket body, the spent structural upper stage left behind in orbit after the launch of a Chinese Long March 2C orbital rocket, in low-Earth orbit for sustained, close-range inspection.

Continuum-1 is a Satellogic-built Earth observation satellite that HEO acquired from Satellogic in December 2025. It was designed to image Earth from several hundred kilometers up and carries an Earth-imaging camera and a fuel reserve sized for that job. After completing a three-maneuver sequence, Continuum-1 held position within 30 kilometers of the target during a first proximity period in August, then closed to within 27 kilometers during a second, closer period in late August and early September. HEO reported today that resolution improved from roughly 8 cm per pixel, shared from the first period, to as sharp as 7 cm per pixel during the second.

“Continuum-1 was built to observe Earth from about 500 kilometers away,” said Gonzalo Castillo, VP of Product & Customer Success at Satellogic. “Getting it to hold a sharp picture of something 27 kilometers away, which meant re-tuning the optical payload and the software behind it, demonstrates the flexibility of our platform to also serve Space Domain Awareness applications.”

This is the second public update on the campaign, following initial images it shared in early September. The campaign was conducted in partnership with HEO, which selected the target and led mission planning, and UNSW Canberra Space, which supported maneuver planning and ground-based tracking, with funding through Australia’s Defence Trailblazer program, while Satellogic was responsible for Mission Operations.

This is the latest proof point of the capabilities Satellogic can provide in support of sovereign missions. The campaign is a demonstration that Satellogic’s satellite fleet is capable of tasks well outside its original design brief, without new hardware or a dedicated mission build. As more infrastructure moves into orbit, that kind of software flexibility will become a sovereign requirement.

About Satellogic

Founded in 2010, Satellogic (NASDAQ: SATL) builds the infrastructure for Persistent Global Intelligence (PGI): continuous, proactive awareness of the places, assets, and activities that matter. The company combines high-cadence satellite collection, best-in-class technology, AI-accelerated workflows, and sovereign-trusted architecture to help customers move from episodic imagery to persistent monitoring programs.

Satellogic serves allied defense and intelligence agencies, civil governments, and commercial markets that need reliable, scalable awareness of change across large portfolios of sites. Customers can begin with discovery, expand into persistent monitoring, and build toward dedicated or sovereign-controlled capacity as their mission requirements grow. To learn more, please visit: https://www.satellogic.com.

About HEO

HEO is building the intelligence layer for space. We image objects in orbit on demand, turning existing satellites into inspection platforms and building our own sensors where coverage gaps remain. Our software automates tasking, capture and analysis, turning imagery into decision-ready intelligence about satellites, debris and other objects in orbit. HEO operates internationally, with offices in Australia, France, Japan, the United Kingdom and the United States. Our goal is to make any image in the Solar System available on Demand. To learn more, please visit: https://www.heospace.com/

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the U.S. federal securities laws. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on Satellogic’s current expectations and beliefs concerning, among other things, the capabilities, performance, and potential applications of Satellogic’s Managed Sovereign Missions, satellite software, and pipeline. Although we believe our plans, intentions and expectations reflected in or suggested by these forward-looking statements are reasonable, we cannot give any assurance that we either will achieve or realize these plans, intentions or expectations. Forward-looking statements are inherently subject to risks, uncertainties and assumptions, including risks related to the performance of satellites and software once in orbit and reliance on third parties. Many actual events and circumstances are beyond the control of the Company. Many factors could cause actual future results to differ materially from the forward-looking statements in this press release, including but not limited to the risks and uncertainties described in the “Risk Factors” section of Satellogic’s Annual Report on Form 10-K and other documents filed or to be filed by Satellogic from time to time with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made. Satellogic assumes no obligation and does not intend to update or revise forward-looking statements, whether as a result of new information, future events, or otherwise.

Contacts

Satellogic Investor Relations:
ir@satellogic.com

Satellogic Media Relations:
pr@satellogic.com

HEO Space:
info@heospace.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5794ca75-17c8-47ce-b7dd-0b08fce26d1a

New Agreement Advances Autonomous, Low-Latency Intelligence Capabilities and Supports the Integration of Six Additional Earth Observation Satellites

PARIS, Sept. 14, 2026 (GLOBE NEWSWIRE) — Satellogic Inc. (NASDAQ: SATL), the infrastructure company for Persistent Global Intelligence (PGI), today announced an expanded agreement with Innovative Defense Technologies (IDT) in support of the U.S. Office of Naval Research (ONR) Slingshot III program. The new work builds on Satellogic’s ongoing role in the Slingshot initiative and will advance faster, more autonomous production of track data, improved predictive planning, and new in-orbit operational capabilities.

Under the agreement, Satellogic will conduct a series of on-orbit activities and tests during 2027 and 2028. The work supports the integration of six new Satellogic NewSat Mark VI satellites into the Slingshot III architecture over the next 18 months, extending the program from proof-of-concept demonstrations toward operationally relevant capabilities.

The activities and testing will encompass enhanced onboard data processing, system feasibility checks, and automated data filtering. Together, these capabilities are designed to accelerate the creation of actionable track data and enable more responsive planning and execution across a distributed satellite system.

“This expanded work is a meaningful step in operationalizing the capabilities we have been proving through Slingshot,” said Emiliano Kargieman, Chief Executive Officer of Satellogic. “By combining high-resolution Earth observation, onboard processing, and inter-satellite communications, we are helping establish a new PGI infrastructure building block for real-time detection, autonomous tip-and-cue, and faster decision-making. We are proud to continue supporting IDT and the Office of Naval Research as they advance the use of commercial space technologies for mission-critical intelligence workstreams.”

Slingshot is an ONR research and development initiative that brings together commercial space capabilities to advance low-latency maritime domain awareness. Earlier phases of the program demonstrated how accelerated image processing, object classification, and track generation can be performed within low-latency requirements using commercial satellites and onboard software.

“This is about redefining the speed of national security,” said Bernie Gauf, IDT Chairman & CEO. “We took capabilities once limited to highly specialized government systems and proved they can be delivered via commercial platforms at the speed the mission demands. This is a leap forward in providing a critical advantage in maritime domain awareness.”

Satellogic’s NewSat Mark VI satellites are designed to extend these capabilities through inter-satellite link (ISL) technology. ISL-enabled satellites can share information across the constellation, creating the foundation for more autonomous workflows in which a detected change or object of interest can inform the tasking of a subsequent satellite without requiring every decision to pass through the ground. The architecture is intended to shorten the data-to-decision timeline and enhance the responsiveness of future missions.

The Slingshot III work also reflects the broader operational relevance of Satellogic’s PGI infrastructure. As the company expands its fleet with ISL-equipped satellites and onboard compute, it is building the capabilities required for a more connected, responsive infrastructure that can deliver timely, actionable insights at scale.

About Satellogic

Founded in 2010, Satellogic (NASDAQ: SATL) builds the infrastructure for Persistent Global Intelligence (PGI): continuous, proactive awareness of the places, assets, and activities that matter. The company combines high-cadence satellite collection, best-in-class technology, AI-accelerated workflows, and sovereign-trusted architecture to help customers move from episodic imagery to persistent monitoring programs.

Satellogic serves allied defense and intelligence agencies, civil governments, and commercial markets that need reliable, scalable awareness of change across large portfolios of sites. Customers can begin with discovery, expand into persistent monitoring, and build toward dedicated or sovereign-controlled capacity as their mission requirements grow. To learn more, please visit: https://www.satellogic.com.

About Innovative Defense Technologies (IDT)

Innovative Defense Technologies (IDT) is an Arlington, Virginia based provider of automated software testing, data analysis and cybersecurity solutions for large, complex, mission-critical systems. Using patented Automated Test and ReTest (ATRT) technology, IDT delivers solutions that enable customers to test, assess and certify software with unprecedented efficiency. The company has been recognized by SECAF as the Government Contractor of the Year; by the Washington Business Journal as one of the 50 Fastest Growing Companies; and by CIO Review as one of the 20 Most Promising Defense Technology Solution Providers. www.IDTus.com.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the U.S. federal securities laws. The words “anticipate”, “believe”, “continue”, “could”, “estimate”, “expect”, “intends”, “may”, “might”, “plan”, “possible”, “potential”, “predict”, “project”, “should”, “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on Satellogic’s current expectations and beliefs concerning, among other things, our plans, strategies, prospects, both business and financial. Although we believe our plans, intentions and expectations reflected in or suggested by these forward-looking statements are reasonable, we cannot give any assurance that we either will achieve or realize these plans, intentions or expectations. Forward-looking statements are inherently subject to risks, uncertainties and assumptions. Generally, statements that are not historical facts, including statements concerning possible or assumed future actions, business strategies, events or results of operations, are forward-looking statements. Many actual events and circumstances are beyond the control of the Company. Many factors could cause actual future results to differ materially from the forward-looking statements in this press release, including but not limited to: (i) our ability to generate revenue as expected, including due to challenges created by macroeconomic concerns, geopolitical uncertainty (e.g., trade relationships), financial market fluctuations and related factors, (ii) our ability to effectively market and sell our Persistent Global Intelligence (“PGI”) services and to convert contracted revenues and our pipeline of potential contracts into actual revenues, (iii) market acceptance of our PGI services and our dependence upon our ability to keep pace with the latest technological advances, including those related to artificial intelligence and machine learning; (iv) risks related to the secured convertible notes, (v) the potential loss of one or more of our largest customers, (vi) the considerable time and expense related to our sales efforts and the length and unpredictability of our sales cycle, (vii) risks and uncertainties associated with defense-related contracts, (viii) risk related to our pricing structure, (ix) our ability to scale production of our satellites as planned, (x) unforeseen risks, challenges and uncertainties related to our expansion into new business lines, (xi) our dependence on third parties, including SpaceX, to transport and launch our satellites into space, (xii) our reliance on third-party vendors and manufacturers to build and provide certain satellite components, products, or services and the inability of these vendors and manufacturers to meet our needs, (xiii) our dependence on ground station and cloud-based computing infrastructure operated by third parties for value-added services, and any errors, disruption, performance problems, or failure in their or our operational infrastructure, (xiv) risk related to certain minimum service requirements in our customer contracts, (xv) our ability to identify suitable acquisition candidates or consummate acquisitions on acceptable terms, or our ability to successfully integrate acquisitions, (xvi) competition for PGI services, (xvii) risks related to changes in tax laws and regulations, including the “One Big Beautiful Bill Act,” (xviii) risks related to changes in trade policy and the related impact on macroeconomic conditions, including further expansions of U.S. export controls and tariffs, as well as related retaliatory actions, (xix) challenges with international operations or unexpected changes to the regulatory environment in certain markets, (xx) unknown defects or errors in our products, (xxi) risk related to the capital-intensive nature of our business and our ability to raise adequate capital to finance our business strategies, (xxii) uncertainties beyond our control related to the production, launch, commissioning, and/or operation of our satellites and related ground systems, software and analytic technologies, (xxiii) the failure of the market for PGI services to achieve the growth potential we expect, (xxiv) risks related to our satellites and related equipment becoming impaired; (xxv) risks related to the failure of our satellites to operate as intended, (xxvi) production and launch delays, launch failures, and damage or destruction to our satellites during launch, and (xxvii) the impact of natural disasters, unusual or prolonged unfavorable weather conditions, epidemic outbreaks, terrorist acts and geopolitical events (including the ongoing conflicts between the United States of America and Iran, Russia and Ukraine, and in the Gaza Strip) on our business and satellite launch schedules. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of Satellogic’s Annual Report on Form 10-K and other documents filed or to be filed by Satellogic from time to time with the Securities and Exchange Commission. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Satellogic assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Satellogic can give no assurance that it will achieve its expectations.

Contacts

Satellogic Investor Relations:
ir@satellogic.com

Satellogic Media Relations:
pr@satellogic.com

Reduces Interest Rate by Four Percentage Points and Lowers Required Collateral

TAMPA, Fla., Sept. 14, 2026 (GLOBE NEWSWIRE) — Upexi, Inc. (NASDAQ: UPXI) (“Upexi” or the “Company”), a leading Solana-focused digital asset treasury company and consumer brands owner, today announced that it has amended its existing credit facility with BitGo Prime, LLC (“BitGo”), first entered into on May 23, 2025 under a Master Loan Agreement. Under the amended terms, the interest rate applicable to the Company’s outstanding borrowings has been reduced from 11.5% to 7.5% per year, and the required collateral level has been reduced to 200%, with a margin call level of 150%.

“Under the amended credit facility, the Company, based on current borrowings outstanding, expects to save over $2 million in interest costs per year and enjoy greater flexibility with a lower collateral requirement,” stated Allan Marshall, Chief Executive Officer of Upexi. “Such action represents our continued efforts to reduce expenses and fortify the balance sheet as we look for more levers to create value for shareholders.”

About Upexi, Inc.
Upexi, Inc. (Nasdaq: UPXI) is a leading digital asset treasury company, where it aims to acquire and hold as much Solana (SOL) as possible in a disciplined and accretive fashion. In addition to benefiting from the potential price appreciation of Solana, the cryptocurrency of the leading high-performance blockchain, Upexi utilizes three key value accrual mechanisms in intelligent capital issuance, staking, and discounted locked token purchases. The Company operates in a risk-prudent fashion to position itself for any market environment and to appeal to investors of all kinds, and it currently holds over two million SOL. Upexi also continues to be a brand owner specializing in the development, manufacturing, and distribution of consumer products. Please see www.upexi.com for more information.

Follow Upexi on X – https://x.com/upexitreasury
Follow CEO, Allan Marshall, on X – https://x.com/upexiallan
Follow CSO, Brian Rudick, on X – https://x.com/thetinyant

Forward-Looking Statements

This news release contains “forward-looking statements” as that term is defined in Section 27A of the United States Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations, or intentions regarding the future. For example, the Company is using forward-looking statements when it discusses the anticipated interest cost savings under the amended credit facility, the availability of borrowings under the facility and its potential future increase, its digital asset treasury strategy, including the accumulation of Solana, and its capital structure. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with business strategy, potential acquisitions, revenue guidance, product development, integration, and synergies of acquiring companies and personnel. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that the beliefs, plans, expectations, and intentions contained in this press release are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K and other periodic reports filed from time-to-time with the Securities and Exchange Commission.

Company Contact
Brian Rudick, Chief Strategy Officer
(203) 442-5391
Brian.rudick@upexi.com

Investor Contact
Valter Pinto or Jack Perkins
KCSA Strategic Communications
Upexi@KCSA.com

New functionality helps DSPs and agency planners create deterministic HCP and consumer audiences faster, using one single workflow

WALTHAM, Mass., Sept. 14, 2026 (GLOBE NEWSWIRE) — OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients at the most important decision points has expanded its patent-pending, AI-powered Natural Language Audience Builder (NLAB) tool to allow media planners and buyers to build both claims-grade HCP audiences and privacy-safe direct-to-consumer (DTC) audiences in the same workflow, from a shared plain-language prompt.

This expansion adds OptimizeRx’s Micro-Neighborhood^® Targeting (MNT) audiences to NLAB, transforming NLAB from an HCP audience-building solution into a platform-agnostic, no-code audience tool for comprehensive life sciences media planning. From a single patient audience description, marketers can create and optimize both NPI lists and consumer segments in minutes, and then seamlessly activate those audiences across programmatic and other major media channels.

Alongside the addition of MNT audiences, the expansion also adds new optimization and media planning functionality specific to the DTC landscape, including:

• Decile-based, interactive breakdowns of audience quality (AQ) and reach, so planners can adjust audience precision and scale in real-time to reflect different campaign goals
• Instant generation of media channel propensities and audience demographics for NLAB-created audiences or natural language audience prompts, so planners can create media mix strategies optimized for their specific brand populations

MNT audiences combine de-identified clinical and consumer data at the ZIP-9 level to create custom, privacy-safe, deterministic audiences with hyperlocal precision, providing a scalable alternative to modeled or probabilistic targeting. As a result of the NLAB integration, non-healthcare-native platforms or marketing agencies can now embed validated healthcare audience intelligence without investing in proprietary data or enterprise data licensing agreements.

“Life sciences marketers need audiences grounded in real healthcare behavior relevant to their brand, not generic segments or modelled proxies,” said Mike Rousselle, Chief AI Officer, OptimizeRx. “By bringing MNT into NLAB, we’re not only giving media planners a more streamlined way to build, refine, and activate consumer audiences, but also enabling the precision that can lead to higher marketing engagement and impact.”

“The more complexity NLAB removes for DSPs, agencies, and their life sciences clients, the easier it becomes to put sophisticated audience intelligence to work,” said Stephen Silvestro, CEO, OptimizeRx. “By making both HCP and consumer audiences available on demand, we can reduce friction for our partners and expand the role OptimizeRx plays across their planning and activation strategies.”

To learn more about NLAB and OptimizeRx’s MNT audience technology, visit www.optimizerx.com/technology.

About OptimizeRx

OptimizeRx is a leading healthcare technology company that’s redefining how life science brands connect with patients and healthcare providers. Our platform combines innovative AI-driven tools like the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood Targeting (MNT) to deliver timely, relevant, and hyper-local engagement. By bridging the gap between HCP and DTC strategies, we empower brands to create synchronized marketing solutions that drive faster treatment decisions and improved patient outcomes.

Our commitment to privacy-safe, patient-centric technology ensures that every interaction is designed to make a meaningful impact, delivering life-changing therapies to the right patients at the right time. Headquartered in Waltham, Massachusetts, OptimizeRx partners with some of the world’s leading pharmaceutical and life sciences companies to transform the healthcare landscape and create a healthier future for all.

For more information, follow the Company on X, LinkedIn or visit www.optimizerx.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “allow”, “build”, “transforming”, “can”, “activate”, “embed”, “validate”, “helps” or other similar words and expressions are intended to identify these forward-looking statements. All statements in this press release that reflect the Company’s expectations, assumptions, projections, beliefs or opinions about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements relating to the ability of DSPs and agency planners to create deterministic HCP and consumer audiences faster, marketers’ ability to seamlessly activate audiences across programmatic and other major media channels, the ability of non-healthcare-native platforms or marketing agencies to embed validated healthcare audience intelligence without investing in proprietary data or enterprise data licensing agreements, the addition of audiences enabling precision leading to higher marketing engagement and impact, and the ability to reduce friction for the Company’s partners by making HCP and consumer audience available on demand. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon the Company’s current expectations and involve assumptions regarding the Company’s business, the economy, and other future conditions that may never materialize or may prove to be incorrect. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties including, but not limited to the effect of government regulation, seasonal trends, dependence on a concentrated group of customers, cybersecurity incidents that could disrupt operations, the ability to keep pace with growing and evolving technology, the ability to maintain contracts with eRx platforms and EHR networks, competition, and other factors discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, and in other filings the Company has made and may make with the SEC in the future. One should not place undue reliance on these forward-looking statements, which speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law.

OptimizeRx Contact
Jennifer Dinkel, SVP Marketing
jdinkel@optimizerx.com

Investor Relations Contact
Douglas Farrell
LifeSci Advisors, LLC
dfarrell@lifesciadvisors.com

Press Inquiries
Matter Communications
optimizerx@matternow.com

Partnership Inquires
Louis Trivento, SVP Strategic Partnerships
ltrivento@optimizerx.com

Vancouver, B.C., Sept. 14, 2026 (GLOBE NEWSWIRE) — Rocket Doctor AI Inc. (CSE: AIDR, OTC: AIRDF, Frankfurt: 939) (“Rocket Doctor AI” or the “Company”), a physician-built, AI-powered healthcare technology company focused on empowering doctors and expanding access to high-quality care, is pleased to provide a brief pre-Town Hall operational update highlighting the Company’s progress in some of its key performance indicators for its United States operations during the first two months of the third quarter of 2026.

Following up on the Company’s announced Q2 2026 financial and operational results on September 1, 2026, and ahead of the global Company Town Hall (see details below and announced in a News Release on 9 September, 2026) scheduled for Monday, September 14, 2026, the Company is delighted to share further key recent operational metrics for its U.S. operations.

• Time: 1300 Pacific Standard Time/1600 Eastern Standard Time
• Link: Zoom Webinar: https://us06web.zoom.us/j/83081404618

The objective of this interim update is to place this information in the public domain prior to the Town Hall.

Key U.S. Operational Milestones (July – August 2026)

• Completed Patient Visits: Completed U.S. patient visits reached 3,625 for the two-month period ending August 31, 2026, representing 93% of the 3,911 completed visits recorded for the entire second quarter (3 months) of 2026.
• Clinical Hours: U.S. clinical hours increased to 1,555 hours for the two months ending August 31, 2026, representing 78% of the 1,987.5 clinical hours recorded for the entire second quarter of 2026.

Revenue Recognition and Timing Lag

As detailed in the Company’s News Release dated September 1, 2026, it should be noted that because the Company currently recognizes certain U.S. revenues on a cash basis, there is a timing lag between the significant increase in patient visits and the corresponding recognition of revenue.

Further, as described in the Company’s interim Q2 Management’s Discussion and Analysis (“MD&A”), available under its profile on SEDAR+ at www.sedarplus.ca , the following should be noted:

(i) In connection with its U.S. operations, the Company distinguishes between in-network and out-of-network patients when determining reimbursement eligibility for patient visits conducted through its platform. For in-network patients, both the patient and the treating physician must be enrolled with the applicable insurance provider, Medicare, or Medicaid for a reimbursement claim to be eligible for payment. For out-of-network patients, the Company has made a strategic decision to permit access to its platform to drive adoption and expand its user base during this early stage of its U.S. market development.
(ii) While reimbursement for out-of-network visits is generally not expected, the Company will nonetheless submit claims on behalf of these visits where possible, as there remains a possibility that certain claims may be approved at the discretion of the payor.
(iii) Consistent with the Company’s overall revenue recognition policy for its U.S. operations, any amounts recovered in respect of out-of-network claims will only be recognized as revenue upon actual cash receipt, reflecting the heightened uncertainty of collection associated with these visits. Management will continue to evaluate its network coverage and payor relationships with a view to converting out-of-network patients and physicians to in-network status over time, which is expected to improve reimbursement rates and provide greater revenue visibility going forward.

About Rocket Doctor AI Inc.

Rocket Doctor AI Inc. delivers physician-built, AI-powered solutions designed to make high-quality healthcare accessible throughout the entire patient journey. A cornerstone of the company’s proprietary technology is the Global Library of Medicine (GLM), a clinically validated decision support system developed with input from hundreds of physicians worldwide.

Alongside the GLM is Rocket Doctor Inc, and its AI-powered digital health platform and marketplace. Having helped empower over 350 MDs to provide care to more than 750,000 patient visits, our proprietary technology software and systems enable doctors to independently launch and manage their own virtual or hybrid in-person practices – improving efficiency, restoring autonomy to MDs, and expanding patient access to care.

By reducing administrative burdens and ensuring greater consistency in care, our technology creates more time for meaningful physician-patient interactions. We are committed to reaching underserved, rural, and remote communities in Canada who often lack access to family doctors and supporting patients on Medicaid and Medicare in the United States. With advanced AI, large language models, and connected medical devices, Rocket Doctor AI is redefining modern healthcare – making it more scalable, equitable, and patient-centered.

To learn more about Rocket Doctor AI Inc’s products and services, contact: www.rocketdoctor.ai or email: info@rocketdoctor.ai

FOR ADDITIONAL INFORMATION, CONTACT:

Dr. Essam Hamza, CEO, Rocket Doctor AI essam.hamza@rocketdoctor.ai

Dr. Bill Cherniak, CEO, Rocket Doctor Inc.bill@rocketdoctor.io

For media inquiries, contact: media@rocketdoctor.ai
Call: +1 (778) 819 8321

Cautionary Statements

This news release contains forward-looking statements relating to the future operations of Rocket Doctor AI Inc. and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects,” “intends,” “plans,” “believes,” “estimates,” “projects,” “forecasts,” “positioned” and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the Company Town Hall, the Company’s growth strategy for the United States and Canada, the Company’s key U.S. operational milestones including completed patient visits and clinical hours, the timing lag between patient visits and revenue recognition, the Company’s cash-basis revenue recognition policy for U.S. operations, the distinction between in-network and out-of-network patients and the reimbursement eligibility criteria applicable to each, the Company’s strategy to permit out-of-network patient access, the submission of claims for out-of-network visits and the possibility that certain claims may be approved at the discretion of the payor, management’s evaluation of network coverage and payor relationships with a view to converting out-of-network patients and physicians to in-network status, the expected changes in reimbursement rates and revenue, and future plans and objectives of Rocket Doctor AI Inc., are forward-looking statements that involve risks and uncertainties. 

Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results, performance, or achievements of the Company to be materially different from any future results, performances, or achievements expressed or implied by such forward-looking statements. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements due to a number of factors and risks.  Risk factors include, but are not limited to, the Company’s ability to grow its U.S. payer relationships; competition in the digital healthcare and telehealth markets; the Company’s ability to attract and retain physicians and patients on its platform; regulatory risks in the healthcare industry in Canada and the United States; reliance on third-party payers and partners; risks associated with the provider credentialing process, including potential delays in onboarding new providers and the Company’s ability to satisfy growing network capacity requirements within anticipated timeframes; risks relating to the Company’s cash-basis recognition of certain U.S. revenues; general economic conditions; and other risks detailed from time to time in the filings made by Rocket Doctor AI Inc. with securities regulators. Additional risk factors are described in the Company’s continuous disclosure filings available on SEDAR+ at www.sedarplus.ca.

The forward-looking statements and forward-looking information are based on assumptions management considers reasonable, including assumptions regarding the continued growth of the Company’s U.S. patient visit volumes and clinical hours; the ability to maintain and expand the Company’s network of licensed physicians and healthcare providers; the Company’s ability to successfully convert out-of-network patients and physicians to in-network status over time; the continued availability and stability of reimbursement from third-party payers; the expected timing between patient visits and revenue recognition; the continued operation and reliability of the Company’s technology platform; the regulatory environment in Canada and the United States remaining consistent with current conditions; general economic and market conditions; and the Company’s ability to retain key personnel and maintain sufficient working capital to fund its operations.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of Rocket Doctor AI Inc. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and Rocket Doctor AI Inc. will only update or revise publicly the included forward-looking statements as expressly required by Canadian securities law.

The Company undertakes no obligation to update forward-looking information except as required by law. This release is not an offer to sell or a solicitation of an offer to buy securities and is not personalized investment advice.